 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
FDA Speeds New HER2-Targeted Drug and Companion Tests to Market
June 13, 2012
FDA Speeds New HER2-Targeted Drug and Companion Tests to Market
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Genentech, Dako Submit Applications to FDA for Herceptin in HER2-Positive Stomach Cancer
June 2, 2010 / Pharmacogenomics Reporter - Mayo Study Finds Expanded Protein Panel Fails to Predict Outcome of Herceptin Treatment
December 16, 2011 / ProteoMonitor - Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor - PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter - During Investor Day, Roche Highlights Personalized Medicine as Key Area for Future Growth
September 12, 2012 / Pharmacogenomics Reporter